TrialBlood cancer journal2020

ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden.

Yu-Hung Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.